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Abstract 
A variety of conditions can result in hypopituitarism and this article 
focuses on the diagnosis, treatment and management of central 
hypoadrenalism and hypothyroidism.  Central hypoadrenalism, if 
untreated, can potentially prove to be fatal and thus it is imperative 
that a timely diagnosis is done and life long supplementation 
instituted. Different glucocorticoid supplementation regimes 
together with possible side effects are discussed.  Life long thyroxine 
replacement is needed for central hypothyroidism. Particular aspects 
regarding the diagnosis and management of central hypothyroidism 
are tackled.  Important elements in the management of these patients, 
so as to ensure suitable supplementation are proper clinical and 
biochemical monitoring together with effective patient education. 
Educational aims
s  To identify best practices in the management of patients who have central 
hypoadrenalism and/or hypothyroidism
s  To outline the necessary tests needed for the diagnosis of central hypoadrenalism and 
hypothyroidism
s  To understand the rationale for supplementation therapy with glucocorticoids and 
thyroxine
s  To better appreciate the role of patient education and proper advice as an essential 
part of management
s  To highlight the monitoring requirements needed for proper titration of 
supplementation dosages
Introduction
The pituitary gland is situated at the 
base of the brain and is divided into the 
anterior and posterior lobes.  The anterior 
pituitary is responsible for the synthesis and 
secretion of adrenocorticotropic hormone 
(ACTH), thyroid-stimulating hormone 
(TSH), luteinizing hormone (LH), follicle-
stimulating hormone (FSH), growth hormone 
(GH) and prolactin.  It has a crucial role in 
the control of the hypothalmo-pituitary-
adrenal axis through its secretion of ACTH, 
released under the inﬂuence of hypothalamic 
corticotropin-releasing hormone (CRH), 
ACTH being responsible for the control of 
cortisol secretion by the adrenals.  Control of 
thyroid hormone production by the thyroid 
through the secretion of TSH, released under 
the inﬂuence of hypothalamic thyrotropin-
releasing hormone (TRH) is another key 
role of the anterior pituitary.    Partial or 
complete insufﬁciency of anterior pituitary 
hormone secretion termed hypopituitarism 
may result from pituitary or hypothalamic 
disease. A variety of conditions can result 
in hypopituitarism besides developmental 
and genetic causes, including various 
tumours such as pituitary adenomas 
and craniopharyngomas, head trauma, 
irradiation, pituitary infarction, empty 
sella syndrome and inﬁltrative diseases.  In 
acquired hypopituitarism, failure of pituitary 
hormones usually follows a particular order 
with loss of GH ﬁrst, followed by LH and 
FSH, than TSH and lastly ACTH.  This order 
may reﬂect their relative importance for 
survival and in fact the more severe clinical 
condition occurs with ACTH deﬁciency 
which if left untreated can be fatal.1 This 
review will focus on the diagnosis and 
management of ACTH and TSH deﬁciencies 
(central hypoadrenalism and hypothyroidism 
respectively). 
Central hypoadrenalism
Diagnosis of central hypoadrenalism
Since serum cortisol levels usually reach a 
peak value at about 0800h, a level less than 
100nmol/L at this time is taken to mean 
that there is cortisol deﬁciency.2  Levels 
of serum cortisol taken at other times of 
the day are not very signiﬁcant in terms 
of the diagnosis of hypoadrenalism. Hence 
a number of dynamic function tests have 
been devised to assess whether a patient 
can mount a suitable elevation in serum 
cortisol in response to stress as happens 
physiologically in a normal person.  The 
test which has been available for many 
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years and still considered to be the gold 
standard is the insulin tolerance test (ITT) 
in which an insulin dose is given to induce 
a hypoglycaemic episode and repeated 
measurements of serum cortisol are taken.3   
Due to the nature of the test, it needs to 
be carried out under medical supervision 
and has some important contraindications 
such as a history of epilepsy, ischaemic 
heart disease or cardiac dysrhythmias.  A 
peak value of 550nmol/L or above has to be 
achieved for the test to indicate adequate 
cortisol stress response.1   A test which is 
simpler and shorter to do and for most cases 
provides adequate results which correlate 
well with an ITT, is the short synachten test 
(SST). In this test 0.25mg of ACTH[1-24] 
[tetracosactrin (Synacthen®)] are injected 
intramuscularly (i.m.) or intravenously (i.v.) 
and serum cortisol levels are measured at 
0, 30 and 60 minutes.  Since the use of the 
SST for evaluation of central hypoadrenalism 
works on the principle that adrenal 
glucocorticoid producing cells will have their 
cortisol producing ability attenuated as a 
result of chronic ACTH deﬁciency, there is 
a time lag until this develops and thus this 
test should not be used to assess patients in 
their early stages after a pituitary insult.4,5  
Another alternative test which could be 
used when an ITT is contraindicated, is the 
glucagon test where 1mg of glucagon is 
injected subcutaneously and measurements 
of serum cortisol are carried out every half 
hour for 4 hours.1,6-8    
Treatment of central hypoadrenalism
In the acute setting when central 
hypoadrenalism is present or suspected, 
the treatment of choice is hydrocortisone 
given through the i.v. or i.m. route. 
Before administering the ﬁrst dose of 
hydrocortisone, if possible a serum sample 
for estimation of cortisol level is taken.  
Usually the dose is 100mg every 6-8 hours, 
together with i.v. saline infusion.  After 
24 hours the dose of hydrocortisone can 
be reduced to 50mg 6 hourly and then, 
if clinically tolerated, changed to oral 
hydrocortisone.1,9 
Long term treatment involves lifelong 
supplementation of glucocorticoids. 
Previously most patients used to be given 
hydrocortisone 20mg as soon as they 
wake up and 10mg in the late afternoon.  
Following studies10 that determined that 
the average daily dose of cortisol secreted 
is 5.7mg/m2 per day or 9.9 ± 2.7 mg/day, 
which is equal to a daily delivered dose of 
15-20mg, usual supplementation dosages 
were revised down to this level.  With 
the knowledge that mimicking the normal 
circadian cortisol rhythm has proven to be 
very difﬁcult, different approaches were 
adopted by various experts: either starting 
with a twice daily dose of hydrocortisone and 
if on clinical assessment, the patient is still 
feeling unwell going up to thrice daily dosing 
or advocating that the replacement dose of 
hydrocortisone be divided into 3 doses from 
the start with typical dosages being a 10mg 
dose taken on rising, 5mg at midday and 
5mg in the early evening.1,11-13  Some experts 
advocated that this thrice daily regime be 
further ﬁne tuned by adopting a weight 
adjusted dosage.11 It is important to note 
that the ﬁrst morning dose of hydrocortisone 
is best taken as soon as the patient wakes 
up with a glass of water and the last dose 
should be taken in the late afternoon rather 
than the evening to prevent unphysiological 
high levels of cortisol in the evening and 
possibly insomnia.1,12 Studies on the relation 
between hydrocortisone dosage and health-
related quality of life suggest that a twice 
daily regimen is superior to a once daily 
dose and perhaps a thrice daily better than 
twice daily although the evidence here is 
not as strong.12,13  In a large study14 on 
2424 hypopituitary patients of whom 1186 
were on hydrocortisone, it was shown that 
while patients who were on hydrocortisone 
had higher levels of total cholesterol, 
triglycerides, HbA1c and a higher waist 
circumference, compared to ACTH-sufﬁcient 
patients, those who were taking a dose of 
hydrocortisone less than 20mg/day did not 
have statistically signiﬁcant differences in 
the metabolic parameters mentioned when 
compared to patients who had an intact 
hypothalamic-pituitary-adrenal axis.  To 
try to mimic the physiological cortisol 
circadian rhythm better, modiﬁed release oral 
formulations of hydrocortisone are currently 
being developed.  The total replacement 
dose needed might be less for those patients 
who have some residual pituitary function as 
evidenced by a subnormal peak response on 
a stimulation test but a normal basal level 
of cortisol. Some patients would even just 
require steroid cover for periods of increased 
stress.1  Mineralocorticoid replacement (Ex. 
Fludrocortisone) is not needed in central 
hypoadrenal patients. 
An important dimension of the 
assessment of proper glucocorticoid 
replacement treatment is regular clinical 
assessments aiming to highlight symptoms/
signs of under or over treatment, although 
one has to appreciate that minor degrees 
of over/under treatment might prove very 
difﬁcult to diagnose on clinical grounds.12,13  
In this context the role and value of cortisol 
day curves is debated by various experts, 
though they may have a role in monitoring 
adequate replacement and avoiding over 
treatment of patients1 or in those who are 
on other drugs which interfere with the 
metabolism of hydrocortisone.13  Another 
method advocated by some experts to help 
assess adequate glucocorticoid replacement 
is taking a serum cortisol level 4 hours 
after ingestion and comparing this level to 
a dosing nomogram.11 Although the effect 
on bone mineral density of patients who are 
on glucocorticoid is debatable, there are 
some studies which suggest a lower bone 
density in such patients particularly in post-
menopausal women. Hence it is reasonable 
to suggest that patients are to be kept on 
the lowest dose of hydrocortisone possible 
and have their bone mineral density followed 
up.12,13  
An important dimension in the 
management of patients who are 
glucocorticoid deﬁcient is their education.  
Patients who are on replacement steroids are 
advised to carry a Steroid Card with them at 
all times and emphasis made on the fact that 
they should not stop taking this treatment 
unless advised otherwise by their doctor.  On 
a practical level, patients should be advised 
to think ahead so that they do not run out 
of the replacement steroid tablets.  They are 
also provided with a phial of hydrocortisone 
100mg to be available for administration in 
emergency settings and adequately educated 
on how this is given if the need arises.  
These patients are advised that they should 
double their usual dose of hydrocortisone 
if they have a major stressful event such 
as a febrile illness unless they are severely 
ill when they might need hydrocortisone 
administration through the i.v. route.1,9,12   
Central hypothyroidism
Diagnosis of central hypothyroidism
The biochemical diagnosis of central 
hypothyroidism is done when a low 
thyroxine (T4) level is noted together with 
an inappropriately normal or low TSH level.  
It is worth noting that tri-iodothyronine 
(T3) levels often remain within normal 
limits even when T4 levels are low and 
thus the measurement of its level might 
not be helpful for diagnosis. A high index 
of suspicion should be maintained in 
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those patients who have conditions which 
could result in hypopituitarism and thus 
central hypothyroidism, such as a history of 
pituitary tumours, previous cranial irradiation 
or cranial injuries.15,16
Treatment of Central Hypothyroidism
The treatment of central hypothyroidism 
is life long thyroxine.  It is important to 
ascertain before starting T4 treatment in a 
patient, that the possibility of coexistent 
hypoadrenalism has been excluded or if 
present is adequately replaced since it 
is well known that T4 increases cortisol 
clearance and thus an adrenal crisis 
might be precipitated in patients who are 
cortisol deﬁcient.  Usually it is advisable 
to start with low doses of T4 such as 25-
50μg daily and than titrating the dose 
every few weeks until the correct dose is 
found.  Elderly patients and those with a 
history of ischaemic heart disease deserve 
special attention in titrating the dose of 
T4.  Several drugs including iron, calcium, 
mineral supplements, aluminium hydroxide 
and sucralfate are known to interfere with 
T4 absorption.  Adverse reactions to T4 
treatment have to do with over replacement 
of T4 and thus will include symptomatic or 
subclinical thyrotoxicosis.  It is important 
to note that in central hypothyroidism 
TSH levels cannot be used as an indicator 
of correct dosage as is done in primary 
hypothyroidism since the TSH response is 
inappropriate.  Thus changes in dosages 
should be done on clinical grounds and 
according to serum T4 levels, aiming to 
keep these in the upper half of the normal 
reference range.15,16  
Conclusion
While not very common, hypopituitarism, 
especially central hypoadrenalism and 
hypothyroidism need to be promptly 
diagnosed and appropriately treated.  While 
aiming to restore normal physiological 
hormonal levels, a structured monitoring 
system, both clinically and biochemically is 
needed to determine the most appropriate 
drug supplementation dosages for a 
particular patient.  Patient information is a 
key component of the management of these 
patients in order to ensure drug treatment 
compliance and minimise potential problems. 
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